Protection of non-human primates against rabies with an adenovirus recombinant vaccine

Virology. 2014 Feb:450-451:243-9. doi: 10.1016/j.virol.2013.12.029. Epub 2014 Jan 9.

Abstract

Rabies remains a major neglected global zoonosis. New vaccine strategies are needed for human rabies prophylaxis. A single intramuscular immunization with a moderate dose of an experimental chimpanzee adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein, resulted in sustained titers of rabies virus neutralizing antibodies and protection against a lethal rabies virus challenge infection in a non-human primate model. Taken together, these data demonstrate the safety, immunogenicity, and efficacy of the recombinant Ad-rabies vector for further consideration in human clinical trials.

Keywords: Adenoviral vaccine; NHP; Rabies virus; VNA.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenoviridae / genetics
  • Adenoviridae / metabolism
  • Animals
  • Antibodies, Viral / immunology
  • Female
  • Gene Expression
  • Genetic Vectors / genetics
  • Genetic Vectors / metabolism
  • Humans
  • Macaca fascicularis
  • Macaca mulatta
  • Male
  • Rabies / immunology
  • Rabies / prevention & control*
  • Rabies / virology
  • Rabies Vaccines / administration & dosage*
  • Rabies Vaccines / genetics
  • Rabies Vaccines / immunology
  • Rabies virus / genetics
  • Rabies virus / immunology*
  • Vaccination
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology
  • Viral Proteins / administration & dosage
  • Viral Proteins / genetics
  • Viral Proteins / immunology

Substances

  • Antibodies, Viral
  • Rabies Vaccines
  • Vaccines, Synthetic
  • Viral Proteins